Alexandria Pharmaceuticals results, Q2 2026
Net profit, assets, equity and cash flow for Q2 2026, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit165 millionEGP · +83.4% vs the same period a year earlier
In short
- Alexandria Pharmaceuticals's net profit for Q2 2026 was about 165 million EGP, up +83.4% from 89.99 million EGP in Q2 2025.
Key lines against the same period a year earlier
This periodQ2 2025Change
Net profit165 million89.99 million+83.4%
Gross profit251 million78.97 million+218.0%
Total assets———
Total liabilities———
Shareholders' equity—847 million—
Total liabilities and equity1.68 billion1.41 billion+19.8%
Operating cash flow—71.17 million—
Investing cash flow—748 thousand—
Financing cash flow-195 million-104 million−86.7%
Net change in cash—-32.46 million—
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Alexandria Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy